Julian Stumpf, Oliver Thomusch, Mirian Opgenoorth, Michael Wiesener, Andreas Pascher, Rainer Peter Woitas, Barbara Suwelack, Markus Rentsch, Oliver Witzke, Thomas Rath, Bernhard Banas, Urs Benck, Claudia Sommerer, Christine Kurschat, Kai Lopau, Julia Weinmann-Menke, Bernd Jaenigen, Evelyn Trips, Christian Hugo
BACKGROUND: We previously reported excellent efficacy and improved safety aspects of rapid steroid withdrawal in the randomized controlled one year 'Harmony' trial with 587 predominantly deceased-donor kidney transplant recipients randomized either to basiliximab or rabbit antithymocyte globulin induction therapy and compared to standard immunosuppressive therapy consisting of basiliximab, low tacrolimus once daily, mycophenolate mofetil, and corticosteroids. METHODS: The five-year post-trial follow-up data were obtained in an observational manner at a three and a five-year visit only for those Harmony patients who consented to participate and covered clinical events that occurred from the second year onwards...
June 30, 2023: Nephrology, Dialysis, Transplantation